Chris Garabedian's incubator leads Series A funding for gene therapy manufacturer/developer combo
Back in December, longtime industry investor Chris Garabedian helped launch a $210 million VC fund for early-stage biotechs. On Tuesday, Garabedian and the Perceptive Xontogeny Venture Fund introduced its latest startup.
The ex-Sarepta CEO has teamed with former Abeona chief Tim Miller to create Forge Biologics, a gene therapy company focusing on both manufacturing and development of GMP adeno-associated viruses, with $40 million in Series A funding. Forge is the eighth biotech in which the PXV Fund has invested — but only the sixth announced — and the first in the gene therapy area, Garabedian told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.